Bausch + Lomb Corporation (BLCO) News
Follow Bausch + Lomb Corporation (BLCO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
US FDA sent warning letter to Bausch & Lomb on September 4
US FDA
REGULATION | Sep 15, 2026, 02:34 PM UTC
L
Leerink Partners sets $24.00 price target for Bausch & Lomb
Leerink Partners announced a $24.00 per-share price target for Bausch & Lomb, according to Benzinga ratings actions cited by TradingView News.
EQUITY | Sep 09, 2026, 03:16 PM UTC
L
Bausch & Lomb target maintained at $21.00 by HC Wainwright
HC Wainwright & Co. maintained its Bausch & Lomb price target at $21.00 per share.
EQUITY | Aug 28, 2026, 10:24 AM UTC
L
Bausch + Lomb advances dry-eye Phase 3 candidate, BL1332 Phase 1b
Bausch + Lomb moves its dual-action dry-eye candidate into Phase 3 after mixed Phase 2 results and reports positive Phase 1b ocular-surface pain data for BL1332.
EQUITY | Aug 24, 2026, 09:07 PM UTC
M
Bausch + Lomb Adds Bausch Health CEO To Board
Bausch Health CEO joins Bausch + Lomb board
EQUITY | Aug 06, 2026, 11:05 AM UTC
L
BLCO Bausch + Lomb Earnings Notes: - Q2 Operating Income $83M - Q2 REV $1.394B vs. EST $1.369B - Q2 Net Income $-14M - Q2 ADJ Net Income $55
BLCO Bausch + Lomb Earnings Notes: - Q2 Operating Income $83M - Q2 REV $1.394B vs. EST $1.369B - Q2 Net Income $-14M - Q2 ADJ Net Income $55M vs. EST $54.9M - Q2 ADJ EPS $0.15 vs. EST $0.15 - Q2 ADJ EBITDA $241M vs. EST
EARNINGS | Jul 29, 2026, 11:03 AM UTC
L
Bausch & Lomb Raises FY2026 Sales Guidance from $5.420B-$5.520B to $5.440B-$5.540B vs $5.468B Est
Bausch & Lomb (NYSE: BLCO ) raises FY2026 sales outlook from $5.420 billion-$5.520 billion to $5.440 billion-$5.540 billion vs $5.468 billion estimate.
EARNINGS | Jul 29, 2026, 10:59 AM UTC
H
BLCO Raises Full-Year 2026 Guidance
BLCO Raises Full-Year 2026 Guidance
EQUITY | Jul 29, 2026, 10:58 AM UTC
L
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutr
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutral rated RXST, Buy rated SGHT) and initiating coverage of Buy rated BLCO, Neutra
EQUITY | Jul 28, 2026, 11:52 AM UTC
L
BLCO Initiated Buy at UBS
BLCO Initiated Buy at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
BLCO bausch + lomb launches eyegility™ inserter preloaded iol delivery system in the United States
BLCO bausch + lomb launches eyegility™ inserter preloaded iol delivery system in the United States
EQUITY | Jul 16, 2026, 11:05 AM UTC
H
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus
Bausch + Lomb Corporation (NYSE: BLCO ) on Thursday said it will discontinue development of BL1107 as a topical treatment for glaucoma after the candidate failed to meet the primary endpoint in a Phase 2 clinical trial.
MNA | Jul 10, 2026, 02:23 PM UTC
H
Bausch + Lomb price target raised to $21 from $19 at Citi
Citi raised the firm's price target on Bausch + Lomb to $21 from $19 and keeps a Buy rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech stocks
EARNINGS | Jul 08, 2026, 10:11 AM UTC